BCAL Diagnostics Limited (BDX.AX)

AUD 0.09

(-2.17%)

Market Cap (In AUD)

32.27 Million

Revenue (In AUD)

3.09 Million

Net Income (In AUD)

-6.4 Million

Avg. Volume

425.64 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.085-0.185
PE
-
EPS
-
Beta Value
0.744
ISIN
AU0000160921
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Shane Ryan M.B.A.
Employee Count
-
Website
https://www.bcaldiagnostics.com
Ipo Date
2021-07-21
Details
BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.